JP5753541B2 - 抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー - Google Patents
抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー Download PDFInfo
- Publication number
- JP5753541B2 JP5753541B2 JP2012546149A JP2012546149A JP5753541B2 JP 5753541 B2 JP5753541 B2 JP 5753541B2 JP 2012546149 A JP2012546149 A JP 2012546149A JP 2012546149 A JP2012546149 A JP 2012546149A JP 5753541 B2 JP5753541 B2 JP 5753541B2
- Authority
- JP
- Japan
- Prior art keywords
- epithelial cells
- glomerular epithelial
- therapy
- urinary
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims description 129
- 201000001474 proteinuria Diseases 0.000 title claims description 105
- 230000001434 glomerular Effects 0.000 claims description 176
- 210000002919 epithelial cell Anatomy 0.000 claims description 175
- 238000000034 method Methods 0.000 claims description 105
- 230000002485 urinary effect Effects 0.000 claims description 100
- 210000002700 urine Anatomy 0.000 claims description 93
- 241000282412 Homo Species 0.000 claims description 27
- 238000011123 anti-EGFR therapy Methods 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 21
- 229960000397 bevacizumab Drugs 0.000 claims description 17
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 13
- 229960001796 sunitinib Drugs 0.000 claims description 13
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 13
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 12
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 229960003787 sorafenib Drugs 0.000 claims description 12
- 238000000684 flow cytometry Methods 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 7
- 210000000557 podocyte Anatomy 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000000463 material Substances 0.000 description 16
- 229940109239 creatinine Drugs 0.000 description 12
- 238000005259 measurement Methods 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 102100036037 Podocin Human genes 0.000 description 4
- 101710162479 Podocin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009535 clinical urine test Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 102000004401 podocalyxin Human genes 0.000 description 3
- 108090000917 podocalyxin Proteins 0.000 description 3
- VYLJAYXZTOTZRR-BTPDVQIOSA-N CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C Chemical compound CC(C)(O)[C@H]1CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@@]3(C)CCCC(C)(C)[C@@H]3[C@@H](O)[C@H](O)[C@@]12C VYLJAYXZTOTZRR-BTPDVQIOSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102100023195 Nephrin Human genes 0.000 description 2
- 102100035604 Synaptopodin Human genes 0.000 description 2
- 101710119889 Synaptopodin Proteins 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- VYLJAYXZTOTZRR-UHFFFAOYSA-N hopane-6alpha,7beta,22-triol Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)C(O)C3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C VYLJAYXZTOTZRR-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108010027531 nephrin Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 102100027209 CD2-associated protein Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000002375 Hand-Foot Syndrome Diseases 0.000 description 1
- 101000914499 Homo sapiens CD2-associated protein Proteins 0.000 description 1
- 101000591211 Homo sapiens Receptor-type tyrosine-protein phosphatase O Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150043340 Kirrel1 gene Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100133707 Mus musculus Npnt gene Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100034086 Receptor-type tyrosine-protein phosphatase O Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940074619 diovan Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28851409P | 2009-12-21 | 2009-12-21 | |
| US61/288,514 | 2009-12-21 | ||
| PCT/US2010/061543 WO2011084791A2 (en) | 2009-12-21 | 2010-12-21 | Early marker of proteinuria in patients treated with an anti-vegf treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515268A JP2013515268A (ja) | 2013-05-02 |
| JP2013515268A5 JP2013515268A5 (enExample) | 2014-02-06 |
| JP5753541B2 true JP5753541B2 (ja) | 2015-07-22 |
Family
ID=44306097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546149A Expired - Fee Related JP5753541B2 (ja) | 2009-12-21 | 2010-12-21 | 抗ｖｅｇｆ治療によって治療された患者におけるタンパク尿の初期マーカー |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20130034861A1 (enExample) |
| EP (1) | EP2517014B1 (enExample) |
| JP (1) | JP5753541B2 (enExample) |
| AU (1) | AU2010339723B2 (enExample) |
| BR (1) | BR112012017767A2 (enExample) |
| CA (1) | CA2785273A1 (enExample) |
| ES (1) | ES2530866T3 (enExample) |
| WO (1) | WO2011084791A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
| ES2530866T3 (es) | 2009-12-21 | 2015-03-06 | Mayo Foundation | Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF |
| EP2940471B1 (en) * | 2012-12-26 | 2019-09-18 | Hara, Masanori | Method for detecting podocytes in urine |
| WO2021055089A1 (en) * | 2019-09-20 | 2021-03-25 | The University Of North Carolina At Chapel Hill | Methods of identifying risk of bevacizumab-induced proteinuria and hypertension |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9306053D0 (en) | 1993-03-24 | 1993-05-12 | Nycomed Pharma As | Method and assay |
| US6969591B2 (en) | 2000-10-27 | 2005-11-29 | Masanori Hara | Method for diagnosing nephropathy |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| EP1481249A1 (en) | 2002-03-07 | 2004-12-01 | Cambridge University Technical Services Limited | Scd fingerprints |
| US20030198959A1 (en) * | 2002-03-28 | 2003-10-23 | Kurnit David M. | Methods and compositions for analysis of urine samples in the diagnosis and treatment of kidney diseases |
| GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| JP2007532913A (ja) | 2004-04-16 | 2007-11-15 | ユニバーシティー オブ マサチューセッツ | 細胞内病原体の検出法および定量化法 |
| AU2005277350A1 (en) * | 2004-08-17 | 2006-03-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy |
| US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
| US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| CA2672560A1 (en) * | 2006-12-15 | 2008-06-26 | Ruprecht-Karls-Universitaet Heidelberg | Methods for treating podocyte-related disorders |
| KR101722033B1 (ko) | 2007-05-21 | 2017-03-31 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 소변으로부터의 전구 세포 및 이를 사용하는 방법 |
| US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
| US20090068683A1 (en) | 2007-06-11 | 2009-03-12 | Mayo Foundation For Medical Education And Research | Markers for preeclampsia |
| CA2703154A1 (en) * | 2007-10-25 | 2009-04-30 | Philogene, Inc. | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| WO2010065968A1 (en) | 2008-12-05 | 2010-06-10 | Myriad Genetics, Inc. | Cancer detection markers |
| EP2442106B1 (en) | 2009-06-10 | 2015-08-19 | Masanori Hara | Method for test on diabetic nephropathy |
| ES2530866T3 (es) | 2009-12-21 | 2015-03-06 | Mayo Foundation | Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF |
| WO2011143499A1 (en) | 2010-05-12 | 2011-11-17 | Tengion, Inc. | Bioactive renal cells |
| CA2875137C (en) | 2012-06-01 | 2021-06-08 | Mayo Foundation For Medical Education And Research | High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia |
| CN104736724A (zh) | 2012-10-05 | 2015-06-24 | 日立化成株式会社 | 尿液外泌小体mRNA和使用其检测糖尿病型肾病的方法 |
| WO2015080838A1 (en) | 2013-11-27 | 2015-06-04 | Mayo Foundation For Medical Education And Research | Detecting podocyte injury in diabetic nephropathy and glomerulonephritis |
-
2010
- 2010-12-21 ES ES10842718T patent/ES2530866T3/es active Active
- 2010-12-21 BR BR112012017767A patent/BR112012017767A2/pt not_active IP Right Cessation
- 2010-12-21 EP EP10842718.8A patent/EP2517014B1/en not_active Not-in-force
- 2010-12-21 JP JP2012546149A patent/JP5753541B2/ja not_active Expired - Fee Related
- 2010-12-21 WO PCT/US2010/061543 patent/WO2011084791A2/en not_active Ceased
- 2010-12-21 CA CA2785273A patent/CA2785273A1/en not_active Abandoned
- 2010-12-21 US US13/518,358 patent/US20130034861A1/en not_active Abandoned
- 2010-12-21 AU AU2010339723A patent/AU2010339723B2/en not_active Ceased
-
2013
- 2013-05-20 US US13/898,124 patent/US9213038B2/en active Active
-
2015
- 2015-11-09 US US14/935,784 patent/US9765137B2/en active Active
-
2017
- 2017-09-13 US US15/703,676 patent/US10336822B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011084791A3 (en) | 2011-11-24 |
| US20180002416A1 (en) | 2018-01-04 |
| ES2530866T3 (es) | 2015-03-06 |
| EP2517014A4 (en) | 2013-07-17 |
| US10336822B2 (en) | 2019-07-02 |
| CA2785273A1 (en) | 2011-07-14 |
| JP2013515268A (ja) | 2013-05-02 |
| WO2011084791A2 (en) | 2011-07-14 |
| US20130296397A1 (en) | 2013-11-07 |
| US20130034861A1 (en) | 2013-02-07 |
| AU2010339723A1 (en) | 2012-08-09 |
| BR112012017767A2 (pt) | 2019-09-24 |
| US9213038B2 (en) | 2015-12-15 |
| AU2010339723B2 (en) | 2014-11-06 |
| US20160060333A1 (en) | 2016-03-03 |
| US9765137B2 (en) | 2017-09-19 |
| EP2517014B1 (en) | 2014-11-19 |
| EP2517014A2 (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2947932C (en) | Pd-l1 antibodies and uses thereof | |
| Wu et al. | Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression | |
| Nurbhai et al. | Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients | |
| ES2791950T3 (es) | Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1) | |
| Jayachandran et al. | Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study | |
| AU2018272054A1 (en) | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers | |
| US10336822B2 (en) | Early marker of proteinuria in patients treated with an anti-VEGF treatment | |
| US20100015643A1 (en) | Method of quantitative determination of antigen protein and quantitative determination kit therefor | |
| EP2841593B1 (en) | Clostridium difficile dehydrogenase and toxin as a biomarker | |
| Custodio et al. | MIBI scintigraphy, indicators of cell proliferation and histology of parathyroid glands in uraemic patients | |
| Lemos et al. | Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa | |
| Chen et al. | Pathological changes of interstitial cells of Cajal and ganglion cells in the segment of resected bowel in Hirschsprung’s disease | |
| EP2541253A1 (en) | Method for examining acute renal disorder | |
| CA2859221C (en) | Lamin a/c and prelamins as indicators of frailty and vulnerability or resiliency to adverse health outcomes | |
| Wasilewska et al. | Urinary OPN excretion in children with glomerular proteinuria | |
| EP4348261A1 (en) | Fibrosis biomarkers for non-alcoholic fatty liver disease | |
| JP2021089221A (ja) | 前がん病変の検出方法及び前がん病変か否かの診断を補助する方法 | |
| Caicedo et al. | Establishing clinically meaningful ranges of metal hypersensitivity in orthopaedic patients using COVID-19 vaccine-induced adaptive immune responses from fully vaccinated adults | |
| WO2025005258A1 (ja) | 急性膵炎における膵炎マーカーの迅速測定法 | |
| Binmadi et al. | Immunophenotyping oral amyloidosis for the precise identification of the biochemical forms: a retrospective study | |
| US20070166774A1 (en) | Functional immunoassay | |
| JP2020505389A (ja) | 子宮内膜症の予後及び治療におけるｃｄ７１受容体の使用 | |
| Pauwels et al. | Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: Protocol for the pragmatic randomised non-inferiority LADI study | |
| Drayson et al. | A355 Monoclonal Antibodies That Provide a Reliable New Assay for Serum Immunoglobulin FLC in Myeloma | |
| NZ701004B2 (en) | Clostridium difficile dehydrogenase and toxin as a biomarker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140723 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140723 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141021 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150427 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150522 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5753541 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |